QR Code

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved

Abstract Background Frailty is a severe, common co‐morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on the clinical benefits of...

Full description

Saved in:
Main Authors: Andrew J.S. Coats, Javed Butler, Hiroyuki Tsutsui, Wolfram Doehner, Gerasimos Filippatos, João Pedro Ferreira, Michael Böhm, Vijay K. Chopra, Subodh Verma, Matias Nordaby, Tomoko Iwata, Daisuke Nitta, Piotr Ponikowski, Faiez Zannad, Milton Packer, Stefan D. Anker
Format: Artigo
Language:Inglês
Published: Wiley 2024-02-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
empagliflozin
frailty
heart failure with preserved ejection fraction
randomized clinical trial
SGLT2 inhibitors
Online Access:https://doi.org/10.1002/jcsm.13393
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items